Your session is about to expire
← Back to Search
Study Summary
This trial will test the safety and effectiveness of a new drug, GSK3745417, for treating cancer. The trial will have two parts, each testing different ways of administering the drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I have had vasculitis in the past.I am fully active or can carry out light work.My organs are functioning well.I am able to understand and sign the consent form.I haven't taken any immune checkpoint inhibitors in the last 28 days.I have had symptoms of pericarditis in the last 6 months.I have not received a live vaccine in the last 30 days.My liver condition is stable.I haven't had allergy desensitization therapy in the last 4 weeks.I have had radiation but still have at least one tumor that wasn't treated with it.I have an autoimmune disease treated with strong medication in the last 2 years.I have a history of serious bleeding or blood clotting issues.I have had issues like severe gut inflammation or blockage in the last 6 months.I have fully recovered from any recent surgeries before starting the study treatment.I am either male or female.My advanced cancer has not responded to, or I cannot tolerate, all proven treatments.I can provide a new tissue sample for testing.I have had a bone marrow or organ transplant.I haven't used any cancer drugs or investigational devices in the last 28 days or within 5 half-lives of the drug.I am not pregnant or breastfeeding and, if capable of becoming pregnant, I am using effective birth control.I have a history or risk of heart problems.I have been treated with a STING agonist before.I have had pneumonitis treated with steroids or have it now.I have a history of specific lung conditions or currently have lung inflammation.I have not had COVID-19 symptoms or known exposure in the last 14 days.I have not used systemic immunosuppressants in the last 28 days.I do not have an active infection needing treatment, HIV, or hepatitis B/C.My cancer is confirmed to be advanced through testing.I have had fluid build-up causing symptoms that were not controlled in the last 6 months.My heart's electrical activity (QTcF) is within normal limits.
- Group 1: Part 2A: Participants receiving GSK3745417 + dostarlimab, Dose escalation Cohort
- Group 2: Part 1A: Participants receiving GSK3745417, Dose-escalation Cohort
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are individuals currently being enrolled in this experiment?
"Confirmatively, this research is currently recruiting patients. The posting was first seen on March 12th 2019 and the last update was November 21st 2022."
Could you summarize any additional investigations that have been conducted surrounding GSK3745417?
"GSK3745417, which was initially examined in 2010 by City of Hope, has already seen 179 trials finished. Currently there are 40 more studies being conducted out of Houston, Texas."
What is the population volume of this research experiment?
"Affirmative. Information found on clinicaltrials.gov indicates that this medical trial is still recruiting participants; the study was first published in March 12th 2019 and recently amended on November 21st 2022. 300 patients need to be recruited at 3 distinct locations."
Has the Food and Drug Administration given its seal of approval to GSK3745417?
"As this trial is in its early stages, the safety of GSK3745417 was assigned a score 1. This means that while efficacy has been preliminarily established, there are limited data points verifying safety."
Share this study with friends
Copy Link
Messenger